Previous 10 | Next 10 |
Synlogic (NASDAQ: SYBX ) -25% in reaction to its decision to terminate development of SYNB1020 for the treatment of hyperammonemia. More news on: Synlogic, Inc., Sarepta Therapeutics, Inc., Fabrinet, Stocks on the move, Read more ...
Gainers : DPW Holdings, Inc. (NYSEMKT: DPW ) +217% . Yuma Energy (NYSEMKT: YUMA ) +210% . DryShips (NASDAQ: DRYS ) +35%. TrovaGene (NASDAQ: TROV ) +32% . Qiwi (NASDAQ: QIWI ) +22% . Houston Wire & Cable (NASDAQ: HWCC ) +22%. China Green Agriculture (NYSE: CGA ) +21%....
DPW Holdings (NYSEMKT: DPW ) +287% as its subsidiary, Digital Power Lending, LLC relaunched monthlyinterest.com More news on: DPW Holdings, Inc., Yuma Energy, Inc., China Green Agriculture, Inc., Stocks on the move, Read more ...
Gainers: Sintx Technologies (NASDAQ: SINT ) +123% . Pivotal Software (NYSE: PVTL ) +67% . SpartanNash Company (NASDAQ: SPTN ) +31% . Entera Bio (NASDAQ: ENTX ) +27% . Bridgeline Digital (NASDAQ: BLIN ) +24% . TrovaGene (NASDAQ: TROV ) +22% . iFresh (NASDAQ: IFMK ) +20% . Leju ...
SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company, developing drugs that target cell division (mitosis), for the treatment of various cancers, including prostate, color...
Trovagene (NASDAQ: TROV ): Q2 GAAP EPS of -$0.79 beats by $0.23 . More news on: TrovaGene, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , Aug. 8, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage Precision Cancer Medicine™ company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced compa...
SAN DIEGO , July 22, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV) , a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company, today announced the acceptance of three abstracts for presentation at the upcoming European Society for Medical Onc...
SAN DIEGO , July 15, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ company, developing targeted therapies to treat cancers with significant medical need for new treatment options, is pleased to release to shareholders ...
Trovagene (NASDAQ: TROV ) has initiated patient enrollment in its Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation. More news on: TrovaGene, Inc...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...